{"name":"Ironshore Pharmaceuticals and Development, Inc","slug":"ironshore-pharmaceuticals-and-development-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"HLD200","genericName":"HLD200","slug":"hld200","indication":"Peripheral T-cell lymphoma (PTCL)","status":"phase_3"}]}],"pipeline":[{"name":"HLD200","genericName":"HLD200","slug":"hld200","phase":"phase_3","mechanism":"HLD200 is a histone deacetylase (HDAC) inhibitor that modulates gene expression by blocking HDAC enzymes.","indications":["Peripheral T-cell lymphoma (PTCL)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNbWRDaGloNHB6MFdTZGZlNVQzZEJ4RlZKV25EZTBJNDJUaTNkWmJVbk1QY1NYU3JyQ1NUbjdTQ1p6ckh1clgxd1dIVU5lNW5iUXVIak5iN1ZST2NGalpCcV9vVE1kQWdRVS1laUtzaUxhV1JnUFhpc0Ntd05jSzNHN0xSVWdvekZQeTg5X0tpTm4zN1lOWkpLODdUMjVSOGFPN0YteWxLeVk?oc=5","date":"2025-07-10","type":"regulatory","source":"The Business Journals","summary":"Cingulate hires chief legal officer ahead of filing for FDA approval - The Business Journals","headline":"Cingulate hires chief legal officer ahead of filing for FDA approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPNl8wZHJxUGtLRUp1VmNpbVRzdWw3SVpBZlV0TkM5NnVpc1RyZ1RCZzdodm1iOF9fRE85R2I2N3ZqUHNWRkZVejVQQXhaV2hYNGpWV0xLSGNxUnN3dE1uZks4UkU2aUFPcTZubEtDY0pTYlNmNHgweGRycy1xRTV3TEJtMVFNZ2NuMGd3SW10TlFnQQ?oc=5","date":"2025-02-27","type":"pipeline","source":"SEC.gov","summary":"Collegium Pharmaceutical, Inc._December 31, 2024 - SEC.gov","headline":"Collegium Pharmaceutical, Inc._December 31, 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNU2ZOLWhadzdBY29HTXBQckhmSDVaYlRjS3F4TmRsdzlRV3dETXNiMW13X2VwNGs5NXdXOHFKR0xlTnR6WnpnbnJyS3B1SW9DSTJ1OHZmU21NcXFWVE9PR1hQV1g0M1BzRDFFdHdHeURsb0xaVHNaclN2dnZnaGdoRkxFTW5qQUdNaC1pcGI5M1lxUWQ5QnBMbGpBZXpBYWFyYXdxamtHT0lCUQ?oc=5","date":"2025-02-27","type":"pipeline","source":"TradingView","summary":"COLLEGIUM PHARMACEUTICAL, INC SEC 10-K Report - TradingView","headline":"COLLEGIUM PHARMACEUTICAL, INC SEC 10-K Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPcFhJOGwzNllzMDRhU0ZDNVQwSEluVXRiR1BpNlhfOTV4b0tfaTFhcXl0bzdkWjcxUHpPeFVRMUI1cGZaVm4zR3loU0NqWFdGd3I3T2VKcEZYRHNRR04taEowVVF3NWtxMXV1Q1dMb1M4cDQyNk0wVVJiNnY5Q1cwdXFUazMyUU1CdEVhWEhOMVljcWpMLXpuWWV2REczMm9f?oc=5","date":"2024-09-04","type":"pipeline","source":"Stock Titan","summary":"Collegium Completes Acquisition of Ironshore Therapeutics - Stock Titan","headline":"Collegium Completes Acquisition of Ironshore Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQZGliZU5TcGxoOHNOWU5YM3gyVGc4OWlkR1dfc1Fkdk5XUDVaTkY2MHBnek1YQlpZY3VyVVFtTzJteE5uMmJxODFUN2JLU25MR3ZaSW4yVjdfNmJrQm92YzZpTVhOczN0V19EWnVwc1BUSEFSVlVJTkdCcElEajYwQmgtejV1dVU?oc=5","date":"2024-08-03","type":"pipeline","source":"businessnc.com","summary":"North Carolina pharma company being sold for $525 million - businessnc.com","headline":"North Carolina pharma company being sold for $525 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQVVh3bE1RSjBiUTRzWlNCQktXY05mYkg0WTNjdERIdlItME5JeEVIYzFtNVhHTG9WNnY4ZEw0cUhIQk9NSnAzRC1POHA1MEJseVU1THg1di1KaTN1aFpfVTBIdmlnd091RDJ3UFA5U2t4cGdBLTVrYXNqRVV2cXlXM1oxWF82NXloV3ZVcUZ5X3RkUWNkRnlXQk9zQnBET1RNbVYzbzd3?oc=5","date":"2024-07-30","type":"deal","source":"Pharmaceutical Technology","summary":"Collegium buys Ironshore for $525m and enter ADHD market - Pharmaceutical Technology","headline":"Collegium buys Ironshore for $525m and enter ADHD market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOT2hNYW5BVjl5NUNKX0xYWXdRUGU0X1JuZUpYM0J5UlNkNFI5UjBqejlXT3JESEJGeDNJWnZQVWpnNU01cE5UUmxDNTlmQlAxblRnTVdCVGxJY1p4MmdTZFJlZjdoOUFUaWUzR0N6amkyY2hfU0l1VjVBRGM3UnViLV9yekk0Q2tYTmdZNDQ5QjJmUmJYUUxvNm9sTnFpNVI2eHlNS3dwRFRZNk91Ul9rMU9TLS1PZlZVUTg0eV9mVFRWQ01vQUJJTDJySmlyd09GOUFpSjYwUWlxU0VC?oc=5","date":"2024-07-29","type":"deal","source":"GlobeNewswire","summary":"Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology - GlobeNewswire","headline":"Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPck9iX2pNRTRFRDBGUFZLOTYzSWFWREU3djFNaFFoQXp0YWxvclp4UTd0VDBKN0puQ3JVZTBMWjJGZFNBbERQUFhmbVRuUTZxN1kzUzM3TndXWEN5dmpPQ29VeVAyVmcyZ0Q3aW5qYTI4b1RzdVJJRXYtNWtjMm9yaERwY2Q3MWlHY0tKRF9wOHYxVTg?oc=5","date":"2024-05-09","type":"pipeline","source":"Yahoo Finance","summary":"Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America - Yahoo Finance","headline":"Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPQXRyX1BwWkpKbnhtaWJwNC1uUW8xcUlsd2ZZMmJDQWlPcF9sNjdxS21weWhNYy1yLTBuY0k3UkdBeXhQV3hmSExUZmo0TWpMaWhoMFhDVnZVcEtNYnp4TGRFVGJVdk9xLTJwMlAycHFvQkVQZE5UQkVNTi1HMmNSUFBDVVFvN1phOV9fLTY2aw?oc=5","date":"2024-02-05","type":"pipeline","source":"Frontiers","summary":"Laboratory School Protocol Mini-Review: Use of Direct Observational and Objective Measures to Assess ADHD Treatment Response Across the Lifespan - Frontiers","headline":"Laboratory School Protocol Mini-Review: Use of Direct Observational and Objective Measures to Assess ADHD Treatment Resp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQSTNmZllObTlrRmNodkNoRGdneU4wLUROUWxfZkpIMHZyMFhBYWc1WEIzLXh5cDFGakNVclJOUWplaDhmTVZ1QUFweG1xN05vdVZHUDRNYVQ0TDN6SVh1WEZ6RWVlZWxCdWFJa3JuUzBRTDkyeDZxdHRUTTl2YWxkUWZRZi1zN203b213eVhDbHQyZHlNZTdqcHR0aFR1bDEzVWFyTjVzak9CajRWdVNQYWFSQzkzb3FmZ1pxZXVxREZhT2U5ZndoY2R6WEhEWDM2RUVLVlJfMG9OVDN2aHRBUDdVc3pyak9hZDE2MQ?oc=5","date":"2022-09-28","type":"pipeline","source":"businesswire.com","summary":"Ironshore Announces Executive Appointments and Strengthening of the Global Business Management Team - businesswire.com","headline":"Ironshore Announces Executive Appointments and Strengthening of the Global Business Management Team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQSVZuTVE5dFAxT0U4SzFaWXBoNklFWmhoSUl5NllLaHZIdzFMdHk4UGEyejBWT0dPdEtaRVl4QmdBbGxESUo1Yjk0c29uclZTaWpCajNiY09MdFlLSUV4UVFwTDJkVUpPTEhHbHFOa0xnNnRLcXRCQWFPTWljTTdiZm1pR1N0akpYdXMwa3E1R3M0ZHd0aVJJc0d2ZHYyRlh1WE1WYUw1ODBEWTVpZGpLRmplYWhXa3pkaUhCZkN4czJPb1ZONzk2TkRhQUJoTS1WU1dDNER1aEl1LTJkWFhqRGZadXQ?oc=5","date":"2021-06-22","type":"regulatory","source":"Psychiatrist.com","summary":"Symptomatic and Functional Response and Remission From the Open-Label Treatment-Optimization Phase of a Study With DR/ER-MPH in Children With ADHD - Psychiatrist.com","headline":"Symptomatic and Functional Response and Remission From the Open-Label Treatment-Optimization Phase of a Study With DR/ER","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOQWtrejdHSkRqRUoxN2NtSEw0OHJKUng2SUtLaVlVNUlMc0RMYUdWeDB0VktSZXVEbXRUY0NJOTJHLW1JZUdvZE43Rlp4LVJ3Q2tDdTlDczFmUkZhYTAzWVFEN01aNWpxOGRIQnU2cUNSMENoaVFUazJUbjhKd1UzalppVzVtOUUyeUlvU3JydGIwMmxhVjZMVzZwcXI4SU4yaWpaNDVzN0RrbW0yNGhmZ3RJRktSR050U3gyc0Y3QzlfN0U3YzNlRUhOM0l4SThCeUZEVnZpVDJkLXBWOXc?oc=5","date":"2019-06-18","type":"pipeline","source":"BioSpace","summary":"ADDING MULTIMEDIA Now Available - JORNAY PM™ (Methylphenidate HCl) CII, the First and Only ADHD Stimulant Dosed in the Evening - BioSpace","headline":"ADDING MULTIMEDIA Now Available - JORNAY PM™ (Methylphenidate HCl) CII, the First and Only ADHD Stimulant Dosed in the E","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}